Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
FOCALIN is a prescription oral tablet containing dexmethylphenidate hydrochloride, the active d-isomer of methylphenidate used to treat attention deficit hyperactivity disorder (ADHD). It is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain. The drug is indicated for ADHD management in pediatric and adult populations.
Product is in late lifecycle phase with modest Part D spending and relatively low claim volume, suggesting a mature franchise with shrinking commercial team investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR
Dexmethylphenidate Hydrochloride Tablets Under Non-Fasting Conditions
Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions
Working on FOCALIN offers exposure to lifecycle management of a mature neuropsychiatric brand in a highly competitive generic-saturated market. This role builds expertise in defensive commercial strategies, payer negotiations, and formulary positioning rather than growth-stage launch experience.
Worked on FOCALIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo